NCT06653296

A Dose-Response Safety Study of ENX-102 in Patients With GAD

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ENX-102 and Determine a Dose-response for ENX-102 in Patients With Generalized Anxiety Disorder (GAD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Engrail Therapeutics INC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD

Conditions

• General Anxiety Disorder

Interventions

Type	Name	Description
DRUG	ENX-102	Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
DRUG	Placebo	Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period

Timeline

• Start date: 2024-12-09
• Primary completion: 2025-06-23
• Completion: 2025-06-23
• First posted: 2024-10-22
• Last updated: 2025-09-17

Locations

3 sites across 1 country: United Kingdom